Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q3 FY21 results · Oct–Dec 2020
Bliss GVS Pharma reported revenue from operations of ₹164.06 crore (up 11.0% from Q3 FY20) and net profit of ₹27.56 crore (up 8.3% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 164.06 | 147.85 | +11.0% | 151.54 | +8.3% |
| Other income | 4.12 | 5.52 | −25.4% | 2.74 | +50.1% |
| Total income | 168.18 | 153.37 | +9.7% | 154.28 | +9.0% |
| Profit before tax | 37.09 | 34.41 | +7.8% | 30.05 | +23.4% |
| Net profit for the period | 27.56 | 25.45 | +8.3% | 21.61 | +27.5% |
| Attributable to shareholders of the company | 25.55 | 23.75 | +7.6% | 20.51 | +24.6% |
| EPS, basic (₹) | 2.48 | 2.30 | +7.8% | 1.99 | +24.6% |
| Net margin (%) | 16.8 | 17.2 | 14.3 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 127.44 | 124.82 | +2.1% | 118.83 | +7.2% |
| Other income | 3.25 | 5.61 | −42.0% | 3.18 | +2.4% |
| Total income | 130.69 | 130.43 | +0.2% | 122.00 | +7.1% |
| Profit before tax | 30.44 | 31.56 | −3.6% | 26.27 | +15.9% |
| Net profit for the period | 22.46 | 23.56 | −4.7% | 18.79 | +19.5% |
| EPS, basic (₹) | 2.18 | 2.28 | −4.4% | 1.82 | +19.8% |
| Net margin (%) | 17.6 | 18.9 | 15.8 |
Consolidated
- Filed with BSE
- 22 Jan 2021, 18:00 IST
- Board meeting
- 21 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Jan 2021, 18:00 IST
- Board meeting
- 21 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE